Dennis S. Charney, MD, one of the researchers behind a groundbreaking new depression treatment, talked to AAMCNews about the early days of research, the medication’s limitations, and its powerful effects on depression.
When the U.S. Food and Drug Administration approved Spravato — a chemical cousin of ketamine — for treatment-resistant depression in March 2019, it brought immediate hope to the roughly 4 million people for whom traditional therapies have been ineffective. Esketamine, delivered via nasal spray in a doctor’s office, is the first new therapy to treat major depression in more than 30 years. But the treatment’s path to approval was a long one, highlighting the importance of federal support for medical research in academic medicine.
Dennis S. Charney, MD, has been one of the leading researchers behind the breakthrough treatment. Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, Charney began examining Ketamine for … Read More